Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $14.1000 (6.17%) ($13.2400 - $14.1000) on Mon. Nov. 30, 2009. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 9.71% (three month average) | RSI | 60 | Latest Price | $14.1000(6.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV declines -4.4% a day on average for past five trading days. | Weekly Trend | VBIV declines -1.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(17%) VWO(12%) EEM(11%) EWG(11%) FXI(11%) | Factors Impacting VBIV price | VBIV will decline at least -4.855% in a week (0% probabilities). TLT(-5%) TIP(1%) SHY(2%) LQD(2%) XLU(4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.855% (StdDev 9.71%) | Hourly BBV | 0 () | Intraday Trend | 5.3% | | | |
|
Resistance Level | $15.19 | 5 Day Moving Average | $15.08(-6.5%) | 10 Day Moving Average | $16.77(-15.92%) | 20 Day Moving Average | $15.19(-7.18%) | To recent high | -30.9% | To recent low | 159.7% | Market Cap | $3.252b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |